Eloisa Rogero-Blanco

Eloisa Rogero-Blanco

Auto-generated profile, based on publicly available information

Eloisa Rogero-Blanco

Primary Health Care Centre General Ricardos, Madrid, Spain

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 August 2020 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JLJuan A Lopez-Rodriguez
Juan A Lopez-Rodriguez
EREloísa Rogero-Blanco
Eloísa Rogero-Blanco
MAMercedes Aza-Pascual-Salcedo
Mercedes Aza-Pascual-Salcedo
FVFernando López Verde
Fernando López Verde
VPVictoria Pico-Soler
Victoria Pico-Soler
MGMULTIPAP group
MULTIPAP group
Multimorbidity is a global health challenge that is associated with polypharmacy, increasing the risk of potentially inappropriate prescribing (PIP). There are tools to improve prescription, such as implicit and explicit criteria. To estimate the prevalence of PIP in a population aged 65 to 74 years with multimorbidity and polypharmacy, according to American Geriatrics Society Beers Criteria® (2015, 2019), the Screening Tool of Older Person’s Prescription -STOPP- criteria (2008, 2014), and the Medication Appropriateness Index -MAI- criteria in primary care. This was an observational, descriptive, cross-sectional study. The sample included 593 community-dwelling elderly aged 65 to 74 years, with multimorbidity and polypharmacy, who participated in the MULTIPAP trial. Socio-demographic, clinical, professional, and pharmacological-treatment variables were recorded. Potentially inappropriate prescribing was detected by computerized prescription assistance system, and family doctors evaluated the MAI. The MAI-associated factors were analysed using a logistic regression model. A total of 4,386 prescriptions were evaluated. The mean number of drugs was 7.4 (2.4 SD). A total of 94.1% of the patients in the study had at least one criterion for drug inappropriateness according to the MAI. Potentially inappropriate prescribing was detected in 57.7%, 43.6%, 68.8% and 71% of 50 patients according to the explicit criteria STOPP 2014, STOPP 2008, Beers 2019 and Beers 2015 respectively. For every new drug taken by a patient, the MAI score increased by 2.41 (95% CI 1.46; 3.35) points. Diabetes, ischaemic heart disease and asthma were independently associated with lower summated MAI scores. The prevalence of potentially inappropriate prescribing detected in the sample was high and in agreement with previous literature for populations with multimorbidity and polypharmacy. The MAI criteria detected greater inappropriateness than did the explicit criteria, but their application was more complex and difficult to automate.

3 March 2020 in JMIR Medical Informatics
Verified
Journal Article
Open access
EREloisa Rogero-Blanco
Eloisa Rogero-Blanco
JLJuan A Lopez-Rodriguez
Juan A Lopez-Rodriguez
TSTeresa Sanz-Cuesta
Teresa Sanz-Cuesta
MAMercedes Aza-Pascual-Salcedo
Mercedes Aza-Pascual-Salcedo
MBM Jose Bujalance-Zafra
M Jose Bujalance-Zafra
MGMultiPAP Group
MultiPAP Group
Background: Multimorbidity is a global health problem that is usually associated with polypharmacy, which increases the risk of potentially inappropriate prescribing (PIP). PIP entails higher hospitalization rates and mortality and increased usage of services provided by the health system. Tools exist to improve prescription practices and decrease PIP, including screening tools and explicit criteria that can be applied in an automated manner. Objective: This study aimed to describe the prevalence of PIP in primary care consultations among patients aged 65-75 years with multimorbidity and polypharmacy, detected by an electronic clinical decision support system (ECDSS) following the 2015 American Geriatrics Society Beers Criteria, the European Screening Tool of Older Person’s Prescription (STOPP), and the Screening Tool to Alert doctors to Right Treatment (START). Methods: This was an observational, descriptive, cross-sectional study. The sample included 593 community-dwelling adults aged 65-75 years (henceforth called young seniors), with multimorbidity (≥3 diseases) and polypharmacy (≥5 medications), who had visited their primary care doctor at least once over the last year at 1 of the 38 health care centers participating in the Multimorbidity and Polypharmacy in Primary Care (Multi-PAP) trial. Sociodemographic data, clinical and pharmacological treatment variables, and PIP, as detected by 1 ECDSS, were recorded. A multivariate logistic regression model with robust estimators was built to assess the factors affecting PIP according to the STOPP criteria. Results: PIP was detected in 57.0% (338/593; 95% CI 53-61) and 72.8% (432/593; 95% CI 69.3-76.4) of the patients according to the STOPP criteria and the Beers Criteria, respectively, whereas 42.8% (254/593; 95% CI 38.9-46.8) of the patients partially met the START criteria. The most frequently detected PIPs were benzodiazepines (BZD) intake for more than 4 weeks (217/593, 36.6%) using the STOPP version 2 and the prolonged use of proton pump inhibitors (269/593, 45.4%) using the 2015 Beers Criteria. Being a woman (odds ratio [OR] 1.43, 95% CI 1.01-2.01; P=.04), taking a greater number of medicines (OR 1.25, 95% CI 1.14-1.37; P<.04), working in the primary sector (OR 1.91, 95% CI 1.25-2.93; P=.003), and being prescribed drugs for the central nervous system (OR 3.75, 95% CI 2.45-5.76; P<.001) were related to a higher frequency of PIP. Conclusions: There is a high prevalence of PIP in primary care as detected by an ECDSS in community-dwelling young seniors with comorbidity and polypharmacy. The specific PIP criteria defined by this study are consistent with the current literature. This ECDSS can be useful for supervising prescriptions in primary health care consultations.

Verified
Journal Article
Open access
PDF file
IGIsabel Del-Cura González
Isabel Del-Cura González
JLJuan A Lopez-Rodriguez
Juan A Lopez-Rodriguez
FLFrancisca Leiva-Fernández
Francisca Leiva-Fernández
Antonio Gimeno-MiguelAntonio Gimeno-Miguel
Antonio Gimeno-Miguel
BPBeatriz Poblador-Plou
Beatriz Poblador-Plou
MGMulti-PAP Group
Multi-PAP Group
(1) Purpose: To investigate a complex MULTIPAP intervention that implements the Ariadne principles in a primary care population of young-elderly patients with multimorbidity and polypharmacy and to evaluate its effectiveness for improving the appropriateness of prescriptions. (2) Methods: A pragmatic cluster-randomized clinical trial was conducted involving 38 family practices in Spain. Patients aged 65–74 years with multimorbidity and polypharmacy were recruited. Family physicians (FPs) were randomly allocated to continue usual care or to provide the MULTIPAP intervention based on the Ariadne principles with two components: FP training (eMULTIPAP) and FP patient interviews. The primary outcome was the appropriateness of prescribing, measured as the between-group difference in the mean Medication Appropriateness Index (MAI) score change from the baseline to the 6-month follow-up. The secondary outcomes were quality of life (EQ-5D-5 L), patient perceptions of shared decision making (collaboRATE), use of health services, treatment adherence, and incidence of drug adverse events (all at 1 year), using multi-level regression models, with FP as a random effect. (3) Results: We recruited 117 FPs and 593 of their patients. In the intention-to-treat analysis, the between-group difference for the mean MAI score change after a 6-month follow-up was −2.42 (95% CI from −4.27 to −0.59) and, between baseline and a 12-month follow-up was −3.40 (95% CI from −5.45 to −1.34). There were no significant differences in any other secondary outcomes. (4) Conclusions: The MULTIPAP intervention improved medication appropriateness sustainably over the follow-up time. The small magnitude of the effect, however, advises caution in the interpretation of the results given the paucity of evidence for the clinical benefit of the observed change in the MAI. Trial registration: Clinicaltrials.gov NCT02866799.

1 December 2020 in Mechanisms of Ageing and Development
Verified
Journal Article
Closed access
FLFrancisca Leiva-Fernández
Francisca Leiva-Fernández
JPJuan Daniel Prados-Torres
Juan Daniel Prados-Torres
APAlexandra Prados-Torres
Alexandra Prados-Torres
IGIsabel Del-Cura González
Isabel Del-Cura González
MCMarcos Castillo-Jimena
Marcos Castillo-Jimena
CMChristiane Muth
Christiane Muth

1 February 2012 in Endocrinología y Nutrición
Verified
Journal Article
Closed access
MBM. Eloísa Rogero Blanco
M. Eloísa Rogero Blanco
MBM. Rosa Albañil Ballesteros
M. Rosa Albañil Ballesteros
MMMagdalena Sánchez Martin
Magdalena Sánchez Martin
ABAlejandro Rabanal Basalo
Alejandro Rabanal Basalo
ADAntonio Olivas Domínguez
Antonio Olivas Domínguez
CLConcepción García Lacalle
Concepción García Lacalle

1 January 2021 in European Journal of General Practice
Verified
Journal Article
Open access
EREloísa Rogero-Blanco
Eloísa Rogero-Blanco
IGIsabel Del-Cura González
Isabel Del-Cura González
MAMercedes Aza-Pascual-Salcedo
Mercedes Aza-Pascual-Salcedo
FGFrancisca García de Blas González
Francisca García de Blas González
CTCarmen Terrón-Rodas
Carmen Terrón-Rodas
GMgroup MULTIPAP
group MULTIPAP
Drug interactions increase the risk of treatment failure, intoxication, hospital admissions, consultations and mortality. Computer-assisted prescription systems can help to detect interactions.To d...